Proactive Research analyst Emma Ulker discusses MaxCyte's (LON:MXCT) commercial momentum across its cell therapy business, which led to 21% year-on-year top-line growth to US $26.2mln in fiscal (FY) 2020.
Ulker says this included three new strategic licences with high profile cell therapy developers, a fourth signed post period, a rise in recurring revenues from instrument leases and disposable sales in cell therapy, accelerated by the receipt of milestone payments from partners.
Click here to read Emma Ulker's update report on 'MaxCyte: 2020 revenues up 21% as industry enters new growth era'
